Moderna has unveiled its first in vivo CAR-T program. Building on other groups' ex vivo CAR-T data,...
Moderna enters in vivo CAR-T, granting autoimmune asset ‘007’ license to kill pathogenic cells
Moderna has unveiled its first in vivo CAR-T program. Building on other groups' ex vivo CAR-T data, the company plans to start clinical development of an...
Author: Fierce Biotech
Read Original Article